Compare Royal Caribbean Cruises Ltd (RCL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Royal Caribbean Cruises Ltd trades at $282.65 (market cap $75.26B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 35.2× Recursion Pharmaceuticals Inc's market cap, and Royal Caribbean Cruises Ltd pays a 2.13% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| RCL | RXRX | |
|---|---|---|
Market Cap | $75.26B | $2.14B |
Volume | 1,958,628 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $6.79 |
52-Week Low | $230.30 | $2.84 |
Typical Hold Time | 85 Days | 22 Days |
Enterprise Value | $97.91B | $1.66B |
Dividend Yield | 2.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $282.36, down 2.25% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamental performance with Q1 and Q2 2026 earnings beats, revenue growth to $17.93B in 2025, and improving profit margins. Recent developments include a $3B investment in Sandals Resorts, expanding into the all-inclusive resort market. Analyst consensus remains positive with a $346.67 price target and 51% buy ratings.
RCL presents a compelling growth story with strong earnings momentum and strategic expansion, though investors face risks from high leverage, fuel cost volatility, and execution challenges from the Sandals acquisition. The stock's current valuation appears reasonable given growth prospects, but requires monitoring of debt levels and integration success.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
